Literature DB >> 11502950

Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors.

D L Leslie1, R A Rosenheck.   

Abstract

OBJECTIVES: This paper presents a profile of the use of antipsychotic medications in the treatment of schizophrenia in a national health system.
METHODS: Prescription drug records written for antipsychotic medications between June 1999 and September 1999 were collected for patients diagnosed with schizophrenia in the Department of Veteran Affairs (VA). Indicators were constructed describing whether patients received multiple antipsychotic medications and whether the total weekly dose was outside of the range specified in the treatment recommendations developed by the schizophrenia Patient Outcomes Research Team (PORT). Generalized estimation equations were used to identify patient and facility characteristics that are associated with adherence to PORT recommendations.
RESULTS: Of the 34,925 patients in the final sample, 2,383 (6.8%) received prescriptions for more than one antipsychotic (polypharmacy). A higher number of patients (4,554 or 13.0%) were dosed above the PORT recommendations on an antipsychotic medication and even more (8,148 or 23.3%) were dosed below the recommended PORT dosage. Older patients, minorities, and those with comorbid depression or substance abuse were generally less likely to receive multiple antipsychotics or be dosed above PORT recommendations. Neither academic emphasis (the percentage of the mental health budget spent on research and education) nor fiscal stress was significantly associated with adherence to recommendations.
CONCLUSIONS: In the nation's largest mental health system, a relatively small number of patients were prescribed multiple antipsychotic medications, but more than a third were dosed outside of the PORT recommended range.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502950     DOI: 10.1097/00005650-200109000-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  20 in total

1.  Use of electronic medical record data for quality improvement in schizophrenia treatment.

Authors:  Richard R Owen; Carol R Thrush; Dale Cannon; Kevin L Sloan; Geoff Curran; Teresa Hudson; Mark Austen; Mona Ritchie
Journal:  J Am Med Inform Assoc       Date:  2004-06-07       Impact factor: 4.497

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 3.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

4.  Antipsychotic combinations for schizophrenia.

Authors:  Nicola Maayan; Karla Soares-Weiser; Jun Xia; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2011

5.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

6.  [Guidelines based on decision support software. Quality management in neurological outpatient schizophrenia treatment].

Authors:  B Janssen; R Menke; F Pourhassan; D Gessner-Ozokyay; R Peters; W Gaebel
Journal:  Nervenarzt       Date:  2006-05       Impact factor: 1.214

7.  Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey.

Authors:  Lorenza Magliano; Andrea Fiorillo; Manuela Guarneri; Cecilia Marasco; Corrado De Rosa; Claudio Malangone; Mario Maj
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

Review 8.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Douglas L Noordsy; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

Review 9.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

10.  Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia.

Authors:  Xinhua S Ren; Lawrence Herz; Shirley Qian; Eric Smith; Lewis E Kazis
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.